Multi-parametric profiling of plasma-derived extracellular vesicles reveals a disease-associated molecular signature supporting a liquid biopsy approach in myelofibrosis.
Blood tests measuring cell particles offer a gentler way to monitor myelofibrosis than repeated bone marrow biopsies.
This study identified a disease-associated EV-based molecular signature in myelofibrosis plasma that supports a non-invasive liquid biopsy approach to disease monitoring. This intersection of hematologic malignancy and liquid biopsy is promising for reducing reliance on bone marrow biopsies in MPN.
What the study was
- Study design
- Biomarker discovery study
- Population
- Myelofibrosis patients (plasma extracellular vesicle profiling)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Molecular Medicine
Why it surfaced
Liquid biopsy approach for myelofibrosis using EV profiling; cross-watchlist interest (hematology + liquid biopsy); exploratory but noteworthy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.